168145.fig.001a
(a)
168145.fig.001b
(b)
168145.fig.001c
(c)
168145.fig.001d
(d)
168145.fig.001e
(e)
168145.fig.001f
(f)
Figure 1: One study patient demonstrated an immune response to a CTA after ipilimumab administration. Plots demonstrating immune titers in each patient to the specified CTA before ipilimumab and at weeks 4, 7, and 10 are presented. Only patient SS-F06 reproducibly showed a weak preexisting serum antibody response to MAGEA3 and MAGEA4, that increased after treatment. Patient SS-F06 also had serum antibodies to CT47 throughout the study that did not change in titers and seroconversion against CSAG2 after the first ipilimumab injection. Patient SS-C03 had some reactivity to SOX2 and had a transient response to CSAG2.